Myocardial infarction (MI) causes cardiomyocyte death and, owing to its low regenerative capacity, damaged tissue is replaced by a fibrotic scar, affecting muscle contractility and leading to heart failure.
Low donor availability means that heart transplantation is not feasible for most patients, making the identification of alternative options an urgent clinical need. Using pluripotent stem cell-derived cardiomyocytes (PSC-CMs) to replace dead cells is a promising therapeutic approach, but the survival and kinetics of these cells after engraftment are poorly understood. Graft rejection has limited the length of follow-up in previous studies, as immunosuppressive agents required for allogeneic PSC-CM survival cannot be tolerated for long.
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.nature.com/articles/s44161-024-00514-z